Nancy U Lin

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
    Nancy U Lin
    Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Breast Cancer Res Treat 133:1057-65. 2012
  2. ncbi request reprint New insights and emerging therapies for breast cancer brain metastases
    Elgene Lim
    Women s Cancers Program, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Oncology (Williston Park) 26:652-9, 663. 2012
  3. doi request reprint Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study
    Ines Vaz-Luis
    Department of Medical Oncology, Dana Farber Cancer Institute, Breast Oncology Center, Boston, MA 02215, USA
    Clin Breast Cancer 13:254-63. 2013
  4. doi request reprint Importance of extracranial disease status and tumor subtype for patients undergoing radiosurgery for breast cancer brain metastases
    Michael A Dyer
    Department of Radiation Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 83:e479-86. 2012
  5. pmc A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases
    Rachel A Freedman
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Harvard Medical School, Boston, MA 02115, USA
    Clin Breast Cancer 11:376-83. 2011
  6. doi request reprint Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype
    Nils D Arvold
    Department of Radiation Oncology, Dana Farber Brigham and Women s Cancer Center, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Breast Cancer Res Treat 136:153-60. 2012
  7. doi request reprint Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases
    Nancy U Lin
    Division of Women s Cancers, Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    J Neurooncol 105:613-20. 2011
  8. doi request reprint Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer
    Nancy U Lin
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:1993-9. 2008
  9. doi request reprint Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer
    Nancy U Lin
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:1452-9. 2009
  10. pmc Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 113:2638-45. 2008

Detail Information

Publications32

  1. pmc A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
    Nancy U Lin
    Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Breast Cancer Res Treat 133:1057-65. 2012
    ..4%) and rash (9.8%). Afatinib monotherapy was associated with promising clinical activity in extensively pretreated HER2-positive breast cancer patients who had progressed following trastuzumab treatment...
  2. ncbi request reprint New insights and emerging therapies for breast cancer brain metastases
    Elgene Lim
    Women s Cancers Program, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Oncology (Williston Park) 26:652-9, 663. 2012
    ..Finally, we will review published and current prospective trials of systemic therapies specifically for BCBM, including novel pathway-specific therapies...
  3. doi request reprint Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study
    Ines Vaz-Luis
    Department of Medical Oncology, Dana Farber Cancer Institute, Breast Oncology Center, Boston, MA 02215, USA
    Clin Breast Cancer 13:254-63. 2013
    ..In this retrospective study, we investigated the clinicopathological features associated with prolonged first-line trastuzumab-based treatment duration...
  4. doi request reprint Importance of extracranial disease status and tumor subtype for patients undergoing radiosurgery for breast cancer brain metastases
    Michael A Dyer
    Department of Radiation Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 83:e479-86. 2012
    ..In this retrospective study, we report on outcomes and prognostic factors for patients treated with stereotactic radiosurgery (SRS) for breast cancer brain metastases...
  5. pmc A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases
    Rachel A Freedman
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Harvard Medical School, Boston, MA 02115, USA
    Clin Breast Cancer 11:376-83. 2011
    ..We observed modest activity with a central nervous system objective response rate of 13.3%; however, median PFS was disappointing. Further studies should focus on other agents to treat this challenging clinical problem...
  6. doi request reprint Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype
    Nils D Arvold
    Department of Radiation Oncology, Dana Farber Brigham and Women s Cancer Center, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Breast Cancer Res Treat 136:153-60. 2012
    ..Women with DM from these two BC subtypes have a high incidence of BM with a short latency, suggesting an ideal target population for trials evaluating the utility of MRI screening...
  7. doi request reprint Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases
    Nancy U Lin
    Division of Women s Cancers, Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    J Neurooncol 105:613-20. 2011
    ..The combination of lapatinib plus topotecan was not active and was associated with excess toxicity...
  8. doi request reprint Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer
    Nancy U Lin
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:1993-9. 2008
    ..We evaluated the safety and efficacy of lapatinib, an oral inhibitor of epidermal growth factor receptor (EGFR) and HER-2, in patients with HER-2-positive brain metastases...
  9. doi request reprint Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer
    Nancy U Lin
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:1452-9. 2009
    ..The current study was done to further evaluate the CNS activity of lapatinib. The study was later amended to allow patients who progressed on lapatinib the option of receiving lapatinib plus capecitabine...
  10. pmc Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 113:2638-45. 2008
    ..The purpose of the current study was to characterize the outcomes of patients with metastatic triple-negative breast cancers, including the risk and clinical consequences of central nervous system (CNS) recurrence...
  11. doi request reprint Heterogeneity of breast cancer and implications of adjuvant chemotherapy
    A Rab Razzak
    Dana Farber Cancer Institute, Boston, MA, USA
    Breast Cancer 15:31-4. 2008
    ..In the future, breast cancer treatment will be more targeted to the tumor and tailored to the individual with the use of genomic and clinical data...
  12. ncbi request reprint Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Invest New Drugs 25:369-75. 2007
    ..Although CT-2103 had activity in this small study, neurotoxicity and hypersensitivity reactions were more frequent in this patient population than expected, and led to early termination of the trial...
  13. doi request reprint A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases
    Nancy U Lin
    Harvard Medical School, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA
    Breast Cancer Res Treat 142:405-14. 2013
    ..Given the high ORR, concurrent lapatinib-WBRT could still be considered for future study with careful safety monitoring. ..
  14. ncbi request reprint Novel approaches to advanced breast cancer: bevacizumab and lapatinib
    Erica L Mayer
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    J Natl Compr Canc Netw 5:314-23. 2007
    ..This review highlights recent advances with the anti-vascular endothelial growth factor antibody, bevacizumab, and the dual kinase inhibitor, lapatinib, in the treatment of metastatic breast cancer...
  15. doi request reprint International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Brigham and Women s Cancer Center, 450 Brookline Avenue, Boston, MA 02215, USA
    Breast 22:203-10. 2013
    ..Moving forward, enhanced efforts to document quality of life over time should be made in order to more fully evaluate the risk/benefit ratio of available options...
  16. ncbi request reprint Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy
    Davinia S E Seah
    From the aDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, and bDepartment of Medical Oncology, The Ohio State University College of Medicine, Columbus, Ohio
    J Natl Compr Canc Netw 12:71-80. 2014
    ..The role of advanced (greater than third) chemotherapy lines in improving survival of all patients with MBC warrants further study. ..
  17. doi request reprint Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Lancet Oncol 14:e407-16. 2013
    ..In this report, the second in a two-part series, we review clinical trials of brain metastases in relation to measures of clinical benefit and provide a framework for the design and conduct of future trials. ..
  18. pmc High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 108:18378-83. 2011
    ..The findings indicate that HSF1 should be evaluated prospectively as an independent prognostic indicator in ER-positive breast cancer. HSF1 may ultimately be a useful therapeutic target in cancer...
  19. doi request reprint Quality of life in long-term survivors of metastatic breast cancer
    Jane L Meisel
    Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Clin Breast Cancer 12:119-26. 2012
    ..Psychosocial distress is common after a diagnosis of breast cancer. Little is known about the psychosocial adjustment of women living long term with metastatic breast cancer...
  20. doi request reprint Advances in adjuvant endocrine therapy for postmenopausal women
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Mayer 232, Boston, MA 02115, USA
    J Clin Oncol 26:798-805. 2008
    ..We outline controversies in choosing the optimal endocrine approach, and we discuss selected ongoing studies. Finally, we highlight future research directions, such as the need to understand host and tumor heterogeneity...
  21. doi request reprint Internal mammary nodes in breast cancer: diagnosis and implications for patient management -- a systematic review
    Ronald C Chen
    Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 26:4981-9. 2008
    ..However, even in patients with visualized primary IMN drainage, the potential benefit of treatment should be balanced against the risk of added morbidity...
  22. pmc Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 118:5463-72. 2012
    ..The objective of this study was to describe clinicopathologic features, patterns of recurrence, and survival according to breast cancer subtype with a focus on triple-negative tumors...
  23. ncbi request reprint Brain metastases: the HER2 paradigm
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 13:1648-55. 2007
    ..Finally, new developments in systemic approaches to the treatment of CNS disease, including cytotoxic chemotherapy and targeted therapy, are explored...
  24. pmc Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer
    Jennifer Y Wo
    Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, MA 02115, USA
    J Clin Oncol 29:2619-27. 2011
    ..In particular, we evaluated whether very small tumor size may predict for increased BCSM relative to larger tumors in patients with extensive LN involvement...
  25. doi request reprint Attitudes of patients with metastatic breast cancer toward research biopsies
    D S Seah
    Deparment of Medical Oncology, Dana Farber Cancer Institute, Boston MA02215, USA
    Ann Oncol 24:1853-9. 2013
    ..Research studies involving human tissue are increasingly common. However, patients' attitudes toward research biopsies are not well characterized, particularly when the biopsies are carried out outside the context of therapeutic trials...
  26. pmc Prospective clinical experience with research biopsies in breast cancer patients
    Ines Vaz-Luis
    Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA
    Breast Cancer Res Treat 142:203-9. 2013
    ..This supports continued efforts to study tissue samples at multiple points in a patient's disease course...
  27. doi request reprint Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA Electronic address
    Lancet Oncol 14:e396-406. 2013
    ..In this two-part series, we review the state of clinical trials of brain metastases and suggest a consensus recommendation for the development of criteria for future clinical trials. ..
  28. doi request reprint Salvage stereotactic radiosurgery for breast cancer brain metastases: outcomes and prognostic factors
    Paul J Kelly
    Department of Radiation Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts, USA
    Cancer 118:2014-20. 2012
    ..The goal of this study was to analyze clinical outcomes and prognostic factors for survival in the salvage setting...
  29. pmc Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342
    Lyndsay N Harris
    Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Breast Cancer Res 8:R66. 2006
    ..We analyzed data from CALGB 9342, which tested three doses of paclitaxel in women with advanced disease, to determine whether response and outcomes differed according to HER2, hormone receptor, and p53 status...
  30. ncbi request reprint CNS metastases in breast cancer
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 22:3608-17. 2004
    ..Studies specifically targeted toward this group of patients are needed...
  31. pmc New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Breast Cancer Res 6:204-10. 2004
    ....
  32. pmc The ethical use of mandatory research biopsies
    Erin M Olson
    Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA
    Nat Rev Clin Oncol 8:620-5. 2011
    ....